May 6, 2020 / 6:39 AM / a month ago

BRIEF-Medivir: FDA Grants MIV-818 ODD For The Treatment Of Hepatocellular Carcinoma

May 6 (Reuters) - Medivir AB:

* FDA GRANTS MIV-818 ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA

* FDA GRANTED ORPHAN DRUG DESIGNATION (ODD) TO MIV-818 FOR TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC), MOST COMMON TYPE OF PRIMARY LIVER CANCER. Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below